European Commission approves Brukinsa to treat marginal zone lymphoma
BeiGene announced that the European Commission has granted marketing authorization of Brukinsa (zanubrutinib) for the treatment of adult patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy
The approval is applicable to all 27 member states of the European Union (EU), plus Iceland and Norway.
BeiGene is focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide. Notably, the EC granted an additional year of marketing protection because the data submitted for the therapeutic indication demonstrated a significant clinical benefit for Brukinsain comparison with existing therapies.
1 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.